Thomas Henthorn
Concepts (350)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ketamine | 6 | 2022 | 103 | 1.780 |
Why?
| | Marijuana Smoking | 2 | 2021 | 256 | 1.050 |
Why?
| | Cannabis | 3 | 2022 | 501 | 0.940 |
Why?
| | Respiratory Insufficiency | 2 | 2019 | 327 | 0.910 |
Why?
| | Dronabinol | 4 | 2022 | 237 | 0.900 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2019 | 310 | 0.880 |
Why?
| | Models, Biological | 27 | 2018 | 1815 | 0.810 |
Why?
| | Hallucinogens | 2 | 2022 | 109 | 0.800 |
Why?
| | Anesthetics, Intravenous | 5 | 2008 | 60 | 0.790 |
Why?
| | Indocyanine Green | 15 | 2004 | 38 | 0.770 |
Why?
| | Fentanyl | 7 | 2009 | 109 | 0.730 |
Why?
| | Dexmedetomidine | 1 | 2022 | 42 | 0.720 |
Why?
| | Analgesia | 2 | 2022 | 99 | 0.700 |
Why?
| | Analgesics | 3 | 2022 | 219 | 0.650 |
Why?
| | Red Meat | 1 | 2019 | 20 | 0.600 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 254 | 0.590 |
Why?
| | Sleep Apnea Syndromes | 1 | 2019 | 90 | 0.590 |
Why?
| | Antipyrine | 9 | 2004 | 12 | 0.580 |
Why?
| | Acute Pain | 1 | 2018 | 50 | 0.530 |
Why?
| | Thiopental | 9 | 2003 | 13 | 0.530 |
Why?
| | Infusions, Intravenous | 12 | 2022 | 413 | 0.500 |
Why?
| | Tissue Distribution | 10 | 2020 | 333 | 0.460 |
Why?
| | Analgesics, Opioid | 5 | 2018 | 1076 | 0.390 |
Why?
| | Pharmacokinetics | 4 | 2003 | 31 | 0.380 |
Why?
| | Coloring Agents | 6 | 2002 | 94 | 0.350 |
Why?
| | Anesthetics, Dissociative | 2 | 2020 | 34 | 0.330 |
Why?
| | Verapamil | 2 | 2009 | 39 | 0.310 |
Why?
| | Anesthesia, Intravenous | 3 | 2008 | 24 | 0.310 |
Why?
| | Loperamide | 1 | 2009 | 12 | 0.300 |
Why?
| | Organic Anion Transporters | 1 | 2009 | 11 | 0.300 |
Why?
| | Anesthetics, Inhalation | 2 | 2000 | 45 | 0.290 |
Why?
| | Dogs | 14 | 2006 | 426 | 0.290 |
Why?
| | Wakefulness | 2 | 2019 | 136 | 0.280 |
Why?
| | Physician Impairment | 1 | 2007 | 11 | 0.280 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2008 | 44 | 0.280 |
Why?
| | Professional Misconduct | 1 | 2007 | 14 | 0.280 |
Why?
| | Cardiac Output | 6 | 2004 | 179 | 0.270 |
Why?
| | Propofol | 2 | 2007 | 86 | 0.270 |
Why?
| | Cannabinoids | 2 | 2021 | 170 | 0.270 |
Why?
| | Hypnotics and Sedatives | 3 | 2022 | 209 | 0.250 |
Why?
| | Inulin | 5 | 2000 | 11 | 0.250 |
Why?
| | Humans | 61 | 2022 | 138651 | 0.240 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2017 | 358 | 0.240 |
Why?
| | Anesthesiology | 1 | 2007 | 116 | 0.240 |
Why?
| | Endothelium, Vascular | 4 | 2002 | 934 | 0.240 |
Why?
| | Alfentanil | 4 | 1996 | 7 | 0.240 |
Why?
| | Ketorolac | 2 | 2017 | 25 | 0.220 |
Why?
| | Academic Medical Centers | 1 | 2007 | 511 | 0.220 |
Why?
| | Splanchnic Circulation | 2 | 2002 | 12 | 0.210 |
Why?
| | Stereoisomerism | 2 | 2021 | 101 | 0.210 |
Why?
| | Pain, Postoperative | 3 | 2017 | 298 | 0.210 |
Why?
| | Lung | 5 | 2009 | 4086 | 0.210 |
Why?
| | Glucuronides | 1 | 2022 | 19 | 0.190 |
Why?
| | Substance-Related Disorders | 2 | 2007 | 1082 | 0.180 |
Why?
| | Substance Abuse Detection | 1 | 2022 | 97 | 0.170 |
Why?
| | Brain | 3 | 2009 | 2782 | 0.170 |
Why?
| | Iatrogenic Disease | 1 | 2021 | 68 | 0.170 |
Why?
| | Hemodynamics | 5 | 2018 | 1090 | 0.170 |
Why?
| | Milk, Human | 2 | 2021 | 153 | 0.170 |
Why?
| | Plasma | 3 | 2020 | 221 | 0.170 |
Why?
| | Midazolam | 3 | 2006 | 68 | 0.160 |
Why?
| | Creatinine | 1 | 2022 | 489 | 0.160 |
Why?
| | Pulmonary Circulation | 3 | 1997 | 436 | 0.160 |
Why?
| | Isoflurane | 1 | 2000 | 39 | 0.160 |
Why?
| | Hepatic Encephalopathy | 1 | 1999 | 22 | 0.160 |
Why?
| | Vancomycin | 1 | 2020 | 80 | 0.160 |
Why?
| | Fibrinolysis | 2 | 1999 | 147 | 0.150 |
Why?
| | Male | 42 | 2022 | 68216 | 0.150 |
Why?
| | Neuromuscular Nondepolarizing Agents | 2 | 1997 | 18 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 121 | 0.150 |
Why?
| | Taurine | 1 | 2019 | 44 | 0.150 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 72 | 0.150 |
Why?
| | Infusions, Intra-Arterial | 1 | 2018 | 61 | 0.150 |
Why?
| | Preoperative Care | 2 | 2020 | 364 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 556 | 0.140 |
Why?
| | Area Under Curve | 6 | 2008 | 315 | 0.140 |
Why?
| | Homocystinuria | 1 | 2019 | 72 | 0.140 |
Why?
| | Receptors, Opioid | 1 | 2018 | 27 | 0.140 |
Why?
| | Halothane | 1 | 1997 | 7 | 0.140 |
Why?
| | Anesthesia, Inhalation | 1 | 1997 | 13 | 0.140 |
Why?
| | Blood-Brain Barrier | 1 | 1999 | 140 | 0.140 |
Why?
| | Prochlorperazine | 2 | 2008 | 10 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2045 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2020 | 412 | 0.140 |
Why?
| | Narcotics | 1 | 1998 | 55 | 0.140 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | Probability | 1 | 2018 | 309 | 0.130 |
Why?
| | Internship and Residency | 1 | 2007 | 1176 | 0.130 |
Why?
| | Mixed Function Oxygenases | 3 | 1999 | 49 | 0.130 |
Why?
| | Lidocaine | 1 | 1997 | 46 | 0.130 |
Why?
| | Animals | 23 | 2009 | 37309 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 308 | 0.130 |
Why?
| | Liver Transplantation | 2 | 2002 | 861 | 0.130 |
Why?
| | Indicators and Reagents | 1 | 1996 | 110 | 0.130 |
Why?
| | Anesthetics, Local | 1 | 1997 | 93 | 0.130 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2055 | 0.120 |
Why?
| | Debrisoquin | 3 | 1989 | 3 | 0.120 |
Why?
| | Extracellular Space | 3 | 1999 | 125 | 0.110 |
Why?
| | Neuromuscular Junction | 1 | 1995 | 62 | 0.110 |
Why?
| | Kinetics | 11 | 2002 | 1654 | 0.110 |
Why?
| | Amnesia | 2 | 2006 | 46 | 0.110 |
Why?
| | Cattle | 5 | 2004 | 996 | 0.110 |
Why?
| | Arm | 1 | 1995 | 108 | 0.110 |
Why?
| | Biomarkers | 5 | 2019 | 4111 | 0.110 |
Why?
| | Carrier Proteins | 1 | 1998 | 739 | 0.100 |
Why?
| | Blood Volume | 4 | 2002 | 65 | 0.100 |
Why?
| | Adult | 24 | 2020 | 38296 | 0.100 |
Why?
| | Rhodamine 123 | 2 | 2004 | 7 | 0.100 |
Why?
| | Gallamine Triethiodide | 2 | 1982 | 3 | 0.100 |
Why?
| | Metabolic Clearance Rate | 6 | 2002 | 114 | 0.100 |
Why?
| | Dextromethorphan | 2 | 1989 | 21 | 0.100 |
Why?
| | Smoking | 2 | 2020 | 1607 | 0.100 |
Why?
| | Propranolol | 2 | 2004 | 45 | 0.100 |
Why?
| | Isoquinolines | 2 | 1989 | 46 | 0.090 |
Why?
| | Injections, Intravenous | 5 | 2011 | 204 | 0.090 |
Why?
| | Pulmonary Artery | 1 | 1998 | 1108 | 0.090 |
Why?
| | Colorado | 1 | 2021 | 4528 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2004 | 229 | 0.090 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 197 | 0.080 |
Why?
| | Anesthesia | 2 | 1985 | 226 | 0.080 |
Why?
| | Regional Blood Flow | 4 | 2004 | 500 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1810 | 0.080 |
Why?
| | Polymorphism, Genetic | 2 | 1989 | 636 | 0.080 |
Why?
| | Cells, Cultured | 5 | 2004 | 4175 | 0.080 |
Why?
| | Limit of Detection | 2 | 2021 | 90 | 0.080 |
Why?
| | Reference Values | 3 | 2017 | 804 | 0.080 |
Why?
| | Levorphanol | 1 | 1989 | 2 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 1989 | 12 | 0.080 |
Why?
| | Dinoprost | 1 | 2009 | 46 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 769 | 0.070 |
Why?
| | Pravastatin | 1 | 2009 | 42 | 0.070 |
Why?
| | Microsomes, Liver | 1 | 1989 | 82 | 0.070 |
Why?
| | Methohexital | 2 | 2000 | 2 | 0.070 |
Why?
| | Biological Transport, Active | 2 | 1999 | 71 | 0.070 |
Why?
| | Binding, Competitive | 1 | 2009 | 196 | 0.070 |
Why?
| | Bupivacaine | 1 | 1988 | 34 | 0.070 |
Why?
| | Piperidines | 2 | 2007 | 215 | 0.070 |
Why?
| | Body Water | 2 | 1999 | 23 | 0.070 |
Why?
| | Electroencephalography | 3 | 2009 | 444 | 0.070 |
Why?
| | Heart Rate | 2 | 2009 | 798 | 0.070 |
Why?
| | Arousal | 1 | 1989 | 156 | 0.070 |
Why?
| | Knee | 1 | 1988 | 69 | 0.070 |
Why?
| | Naloxone | 1 | 2009 | 124 | 0.070 |
Why?
| | Middle Aged | 15 | 2018 | 33792 | 0.070 |
Why?
| | Biological Availability | 3 | 2017 | 138 | 0.070 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 108 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 286 | 0.070 |
Why?
| | Camptothecin | 1 | 2007 | 122 | 0.070 |
Why?
| | Time Factors | 5 | 2008 | 6877 | 0.060 |
Why?
| | Cocaine | 1 | 1989 | 172 | 0.060 |
Why?
| | Vecuronium Bromide | 2 | 1997 | 7 | 0.060 |
Why?
| | Female | 29 | 2020 | 73913 | 0.060 |
Why?
| | Acetaminophen | 2 | 2001 | 268 | 0.060 |
Why?
| | Arthroscopy | 1 | 1988 | 236 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 250 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 570 | 0.060 |
Why?
| | Ultrasonics | 2 | 2004 | 50 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2003 | 1320 | 0.060 |
Why?
| | Data Collection | 1 | 2007 | 663 | 0.050 |
Why?
| | Pharmaceutical Preparations | 2 | 1986 | 179 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2007 | 613 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 1999 | 159 | 0.050 |
Why?
| | GABA Modulators | 1 | 2003 | 13 | 0.050 |
Why?
| | Algorithms | 3 | 2003 | 1718 | 0.050 |
Why?
| | Consciousness | 1 | 2003 | 29 | 0.050 |
Why?
| | Anesthesia, General | 2 | 1996 | 105 | 0.050 |
Why?
| | Pharmacology | 1 | 2003 | 11 | 0.050 |
Why?
| | Adolescent | 8 | 2020 | 21528 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2006 | 257 | 0.050 |
Why?
| | Hematocrit | 2 | 2002 | 104 | 0.050 |
Why?
| | Semantics | 1 | 2003 | 95 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2494 | 0.050 |
Why?
| | Capillaries | 2 | 2004 | 111 | 0.050 |
Why?
| | Body Fluid Compartments | 1 | 1982 | 7 | 0.050 |
Why?
| | Computer Simulation | 3 | 2003 | 994 | 0.050 |
Why?
| | Aging | 3 | 2003 | 1859 | 0.050 |
Why?
| | Statistics as Topic | 2 | 1996 | 299 | 0.050 |
Why?
| | DNA | 1 | 2009 | 1449 | 0.050 |
Why?
| | Rats | 2 | 2009 | 5594 | 0.050 |
Why?
| | Body Fluids | 1 | 1982 | 71 | 0.050 |
Why?
| | Preanesthetic Medication | 3 | 1998 | 5 | 0.050 |
Why?
| | Child | 7 | 2020 | 21883 | 0.050 |
Why?
| | Memory | 1 | 2003 | 256 | 0.050 |
Why?
| | Hypoxia | 1 | 2009 | 1137 | 0.050 |
Why?
| | Age Factors | 4 | 2017 | 3274 | 0.050 |
Why?
| | Liver Failure | 1 | 2002 | 87 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 121 | 0.040 |
Why?
| | Drug Resistance, Multiple | 1 | 2000 | 24 | 0.040 |
Why?
| | Postoperative Period | 1 | 2002 | 355 | 0.040 |
Why?
| | Hydroxylation | 3 | 1989 | 45 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2017 | 591 | 0.040 |
Why?
| | Carbon Monoxide | 1 | 2000 | 85 | 0.040 |
Why?
| | Protein S | 1 | 1999 | 10 | 0.040 |
Why?
| | Antithrombin III | 1 | 1999 | 16 | 0.040 |
Why?
| | Living Donors | 1 | 2002 | 301 | 0.040 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2001 | 127 | 0.040 |
Why?
| | Electromyography | 2 | 1997 | 395 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 57 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 449 | 0.040 |
Why?
| | Liver Function Tests | 1 | 1999 | 108 | 0.040 |
Why?
| | Protein C | 1 | 1999 | 52 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 359 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2003 | 1053 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 856 | 0.040 |
Why?
| | Nitrogen Isotopes | 1 | 1999 | 72 | 0.040 |
Why?
| | Magnesium | 1 | 1999 | 158 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 1999 | 112 | 0.040 |
Why?
| | Urea | 1 | 1999 | 79 | 0.040 |
Why?
| | Child, Preschool | 5 | 2020 | 11130 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 1999 | 89 | 0.040 |
Why?
| | Homocysteine | 1 | 2019 | 160 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2004 | 792 | 0.040 |
Why?
| | Infant | 3 | 2020 | 9565 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1748 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 202 | 0.040 |
Why?
| | Oxidative Stress | 2 | 2019 | 1326 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 25 | 0.030 |
Why?
| | Brachial Artery | 1 | 2019 | 203 | 0.030 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 1997 | 12 | 0.030 |
Why?
| | Infusion Pumps | 1 | 1997 | 34 | 0.030 |
Why?
| | Pain | 2 | 2022 | 775 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 2017 | 68 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 227 | 0.030 |
Why?
| | Desipramine | 2 | 1989 | 11 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 156 | 0.030 |
Why?
| | Mathematical Computing | 1 | 1996 | 12 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 208 | 0.030 |
Why?
| | Aerosols | 2 | 2008 | 181 | 0.030 |
Why?
| | Tonsillectomy | 1 | 1998 | 95 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2017 | 593 | 0.030 |
Why?
| | Pancuronium | 1 | 1995 | 5 | 0.030 |
Why?
| | Atracurium | 1 | 1995 | 14 | 0.030 |
Why?
| | Androstanols | 1 | 1995 | 20 | 0.030 |
Why?
| | Tourniquets | 1 | 1995 | 23 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 13322 | 0.030 |
Why?
| | Renal Dialysis | 1 | 1999 | 439 | 0.030 |
Why?
| | Phenotype | 4 | 1989 | 3160 | 0.030 |
Why?
| | Energy Metabolism | 1 | 1999 | 924 | 0.020 |
Why?
| | Melanoma | 1 | 1999 | 766 | 0.020 |
Why?
| | Software | 1 | 1998 | 667 | 0.020 |
Why?
| | Mathematics | 1 | 1992 | 101 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1992 | 136 | 0.020 |
Why?
| | Injections | 1 | 1992 | 190 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2861 | 0.020 |
Why?
| | Drug Interactions | 2 | 2004 | 411 | 0.020 |
Why?
| | Pentobarbital | 2 | 1996 | 18 | 0.020 |
Why?
| | Protein Binding | 2 | 2009 | 2236 | 0.020 |
Why?
| | Administration, Rectal | 2 | 2001 | 13 | 0.020 |
Why?
| | Mephenytoin | 1 | 1989 | 1 | 0.020 |
Why?
| | Hydantoins | 1 | 1989 | 6 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 190 | 0.020 |
Why?
| | Spain | 1 | 1989 | 45 | 0.020 |
Why?
| | Diazepam | 1 | 1989 | 34 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 1989 | 31 | 0.020 |
Why?
| | Infusions, Parenteral | 3 | 1984 | 44 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 114 | 0.020 |
Why?
| | Aged | 6 | 1999 | 24182 | 0.020 |
Why?
| | Diffusion | 1 | 1989 | 121 | 0.020 |
Why?
| | Injections, Intra-Articular | 1 | 1988 | 58 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1989 | 105 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 1999 | 2161 | 0.020 |
Why?
| | Tubocurarine | 1 | 1987 | 6 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2857 | 0.020 |
Why?
| | Drug Combinations | 1 | 1989 | 345 | 0.020 |
Why?
| | Neuromuscular Blocking Agents | 1 | 1987 | 26 | 0.020 |
Why?
| | Body Weight | 3 | 1999 | 990 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 1946 | 0.020 |
Why?
| | Lactic Acid | 1 | 2009 | 306 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 251 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 357 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1093 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 343 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 551 | 0.020 |
Why?
| | Mice, Nude | 1 | 2007 | 689 | 0.020 |
Why?
| | Cardiopulmonary Bypass | 1 | 1987 | 215 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 252 | 0.010 |
Why?
| | Anesthetics | 1 | 1986 | 93 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1989 | 1079 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1261 | 0.010 |
Why?
| | Altitude | 1 | 2009 | 467 | 0.010 |
Why?
| | Aminocaproates | 1 | 1984 | 3 | 0.010 |
Why?
| | Aminocaproic Acid | 1 | 1984 | 4 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 2004 | 82 | 0.010 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2004 | 74 | 0.010 |
Why?
| | Etomidate | 1 | 1983 | 8 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 111 | 0.010 |
Why?
| | Metabolomics | 1 | 2009 | 692 | 0.010 |
Why?
| | Factor Analysis, Statistical | 1 | 2003 | 294 | 0.010 |
Why?
| | Memory Disorders | 1 | 2003 | 175 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1999 | 135 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2004 | 320 | 0.010 |
Why?
| | Imidazoles | 1 | 1983 | 240 | 0.010 |
Why?
| | Capillary Permeability | 1 | 1982 | 146 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 150 | 0.010 |
Why?
| | Cerebrovascular Circulation | 1 | 2004 | 266 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1993 | 7683 | 0.010 |
Why?
| | United States | 1 | 2019 | 15018 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 364 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1229 | 0.010 |
Why?
| | Procainamide | 1 | 1981 | 6 | 0.010 |
Why?
| | Hot Temperature | 1 | 2004 | 394 | 0.010 |
Why?
| | Cyclosporins | 1 | 2000 | 71 | 0.010 |
Why?
| | Theophylline | 1 | 1980 | 42 | 0.010 |
Why?
| | Anti-Arrhythmia Agents | 1 | 1981 | 111 | 0.010 |
Why?
| | Blood Proteins | 1 | 1982 | 248 | 0.010 |
Why?
| | Synaptic Transmission | 1 | 1982 | 295 | 0.010 |
Why?
| | Plasma Substitutes | 1 | 1999 | 5 | 0.010 |
Why?
| | Bryostatins | 1 | 1999 | 2 | 0.010 |
Why?
| | Hypovolemia | 1 | 1999 | 11 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2007 | 3406 | 0.010 |
Why?
| | Macrolides | 1 | 1999 | 67 | 0.010 |
Why?
| | Platelet Activation | 1 | 1999 | 95 | 0.010 |
Why?
| | Dialysis Solutions | 1 | 1999 | 22 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2000 | 949 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 176 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2000 | 418 | 0.010 |
Why?
| | Suppositories | 1 | 1997 | 3 | 0.010 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 1997 | 6 | 0.010 |
Why?
| | Intraoperative Period | 1 | 1997 | 67 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 711 | 0.010 |
Why?
| | Cognition | 1 | 2003 | 1176 | 0.010 |
Why?
| | Administration, Oral | 1 | 1998 | 789 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3642 | 0.010 |
Why?
| | Unconsciousness | 1 | 1994 | 21 | 0.010 |
Why?
| | Half-Life | 1 | 1993 | 147 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2007 | 10938 | 0.010 |
Why?
| | Mice | 2 | 2007 | 17848 | 0.010 |
Why?
| | Body Height | 1 | 1993 | 196 | 0.010 |
Why?
| | Movement | 1 | 1993 | 283 | 0.010 |
Why?
| | Kidney | 1 | 1999 | 1480 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3311 | 0.010 |
Why?
| | Regression Analysis | 1 | 1993 | 1015 | 0.010 |
Why?
| | Nordazepam | 1 | 1989 | 1 | 0.000 |
Why?
| | Benzodiazepines | 1 | 1989 | 154 | 0.000 |
Why?
| | Hip Prosthesis | 1 | 1987 | 46 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 2058 | 0.000 |
Why?
| | Sufentanil | 1 | 1986 | 3 | 0.000 |
Why?
| | Hypothermia, Induced | 1 | 1987 | 86 | 0.000 |
Why?
| | Methods | 1 | 1986 | 67 | 0.000 |
Why?
| | Prospective Studies | 1 | 1998 | 7639 | 0.000 |
Why?
| | Body Mass Index | 1 | 1993 | 2385 | 0.000 |
Why?
| | Droperidol | 1 | 1983 | 5 | 0.000 |
Why?
| | Reflex, Pupillary | 1 | 1983 | 6 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1033 | 0.000 |
Why?
| | Acecainide | 1 | 1981 | 2 | 0.000 |
Why?
| | Aminophylline | 1 | 1980 | 12 | 0.000 |
Why?
| | Respiration | 1 | 1981 | 207 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1981 | 569 | 0.000 |
Why?
| | Asthma | 1 | 1980 | 1889 | 0.000 |
Why?
|
|
Henthorn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|